Langerud, Jonas
Eilertsen, Ina A.
Moosavi, Seyed H.
Klokkerud, Solveig M. K.
Reims, Henrik M.
Backe, Ingeborg F.
Hektoen, Merete
Sjo, Ole H.
Jeanmougin, Marine
Tejpar, Sabine http://orcid.org/0000-0003-3281-8643
Nesbakken, Arild
Lothe, Ragnhild A. http://orcid.org/0000-0002-1693-1032
Sveen, Anita http://orcid.org/0000-0001-8219-6251
Funding for this research was provided by:
Ministry of Health and Care Services | Helse Sør-Øst RHF (2019042, 2023101, 2017102, 2021058)
Norges Forskningsråd (287899, 250993)
Kreftforeningen (208336-2019, 223319-2021)
Article History
Received: 23 August 2023
Accepted: 8 May 2024
First Online: 21 May 2024
Competing interests
: A.N., R.A.L. and A.S. are co-inventors of a patent application regarding the use of HSP90 inhibitors in relation to the consensus molecular subtypes of colorectal cancer (PCT/IB2018/000042). S.H.M., R.A.L. and A.S. are co-inventors of a patent application describing transcriptomic liver metastasis subtypes (LMS) of colorectal cancers (Attorney Docket No. INVEN-39613.101). The authors declare that they have no other competing interests.